PDL BioPharma (PDLI) to Receive Royalties from Perjeta Sales (RHHBY)

Article Stock Quotes (2) Comments (0)

PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) reports that Roche's (OTCBB: RHHBY) Genentech has notified PDL that Pertuzumab, brand name Perjeta, is a licensed product. PDL will receive royalties on sales of Perjeta in the quarter following the first quarter of Perjeta sales in accordance with Genentech's license agreements with PDL. Based on Genentech's public statements, PDL anticipates Perjeta will enter the market later this month.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Merck (MRK) Says Efficacy Not Achieved in Preladenant Phase 3s; Will Discontinue
• St. Jude Medical (STJ) Issues Encouraging Update for EnligHTN™ Multi-Electrode Renal Denervation System Following One Year
• Biogen Idec (BIIB) Appoints Spyros Artavanis-Tsakonas as CSO

Create E-mail Alert Related Categories

Corporate News, FDA

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?